Low Versus High Intensity Laser Therapy on Primary Dysmenorrhea
NCT ID: NCT05448027
Last Updated: 2022-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
52 participants
INTERVENTIONAL
2022-09-30
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
NSAIDs are the first therapeutic line for primary dysmenorrhea; however, they might be accompanied by some undesirable side effects, such as dyspepsia, headache and drowsiness .
Laser treatment is non-invasive, painless, and can be easily administered in primary care settings for a wide range of conditions. Laser treatment significantly reduces pain level in both acute and chronic painful conditions by increasing the production of endorphins.
Low intensity laser therapy (LTTT) as a physical therapy modality with variety of therapeutic effects. There are various researches concluded that it is a safe therapeutic modality for the treatment of dysmenorrhea .
More recently, the pulsed neodymium-doped yttrium aluminum garnet (Nd:YAG) , a form of high-intensity laser therapy (HILT), was introduced to the field of physical therapy. The use of pulsed Nd:YAG lasers with high peak powers (3kW) and wave length of 1064 nm has been increasing and is considered as a non painful and non invasive modality that can stimulate areas that can't be reached with the low power lasers with patients reporting more significant pain reduction . Studies have documented the anti-inflammatory, anti-edematous, and analgesic effects of Nd:YAG lasers, justifying their use in patients with pain issues .
In fact, the HILT program is effective and has a more prolonged effect in pain reduction, and improving QOL with effects lasting up to 12 weeks post-treatment .
There is limited literature regarding the clinical results of high intensity laser treatment for primary dysmenorrhea , this may be contributed to its high cost. So, this research is an attempt to add to the clinical knowledge in this field as it will investigate the difference between the effect of low and high intensity laser therapy on primary dysmenorrhea with the quality of life improvement being the main point of concern .
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Shockwave Therapy on Low Back Pain in Primary Dysmenorrhea
NCT06762106
Effect of Extracorporeal Shock Therapy for Dysmenorrhea
NCT04741243
Effect of Low Level Laser Therapy and Pelvic Stabilisation Exercises on Postpartum Pelvic Girdle Pain
NCT03606720
Strength Profile of Hip Joint in Females With Primary Dysmenorrhea During Menstrual Cycle
NCT06615037
US vs Low Level Laser on Sacroiliac Postpartum
NCT06141954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All females will be randomly divided into two equal groups:
* Group (A): lt will include 26 participants suffering from primary dysmenorrhea who will receive low intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation).
* Group (B): It will include 26 participants suffering from primary dysmenorrhea who will receive high intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation ).
All females will be given a full explanation of the study protocol and a consent form will be signed by each female before entry in this study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low intensity laser therapy group
• Group (A): lt will include 26 participants suffering from primary dysmenorrhea who will receive low intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
Low intensity laser therapy
It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
High intensity laser therapy group
Group (B): It will include 26 participants suffering from primary dysmenorrhea who will receive high intensity laser therapy 3 sessions per cycle for 3 consecutive cycles (one session will be applied the day before menstruation and the other two sessions on the 1st and 2nd days of menstruation
High intensity laser therapy
It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low intensity laser therapy
It will be applied for Group (A), by a pulsed diode low intensity laser device (Endolaser 422 Cp 400, Enraf - nonius apparatus) (Enraf, Rootterdam, Netherlands). with a wave length of 905 nm, mean power output of 400 mWatt, frequency of 10000 Hz and dose of 300 J/cm² . Laser probe will be applied perpendicularly and directly with an irradiation time of 30 sec for each point
High intensity laser therapy
It will be applied for Group (B), by pulsed high intensity laser therapy with pulsed Nd:YAG laser produced by HIRO 3.0 devices (ASA, Arcugnano, Vicenza , Italy). The high intensity laser therapy apparatus used postulates (Nd:YAG), with pulsed emission of wave length ( 1064nm ), very high power peaks (3kW), high intensity obtained (up to 15,000 W/cm2), high level of fluency/energy density (510-1,780 mJ/cm), very short pulse duration (120-150 μs), low frequency (10-40 Hz), duty cycle of about 0.1 % and total energy of 880 J
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All females will be clinically diagnosed by gynaecologist with primary dysmenorrhea .
* Score ≥ 50 or moderate on Menstrual Distress questionnaire (MDQ)
* Their ages will range from 18-25 years old.
* Their BMI will be less than 30 kg/m² (El-Kosery et al., 2020).
* Being virgin.
* Having regular menstruation for the last 6 months (every 28-30 days with no intermittent bleeding).
Voluntary acceptance to participate in the study
Exclusion Criteria
* Systematic chronic diseases , adenomyosis, pelvic inflammatory disease.. etc
* Mental disability .
* Professional athletes (Jill et al., 2012).
* Secondary dysmenorrhea pathology.
* Menstrual irregularity.
* Using hormonal contraception (such as contraceptives and injections) .
* Epileptic fits .
* Cardiac pacemakers.
* Lumbar disc lesions .
18 Years
25 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nermine Ahmed Mohamed Ahmed El Labbad
Principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
012/003428
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.